1. Employing ATP as a New Adjuvant Promotes the Induction of Robust Antitumor Cellular Immunity by a PLGA Nanoparticle Vaccine
- Author
-
Jinrong He, Xu Yang, Liangqun Hua, Yongjun Chen, Weiwei Huang, Chao Ye, Hongmei Bai, Mingcui Yuan, Zhongqian Yang, Fulan Gao, Sijin Li, Yanbing Ma, Qishu Zhang, Wenjia Sun, and Weiran Li
- Subjects
0301 basic medicine ,Cellular immunity ,Materials science ,Papillomavirus E7 Proteins ,medicine.medical_treatment ,Transplantation, Heterologous ,Antigen-Presenting Cells ,Tumor vaccines ,Cancer Vaccines ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,Adenosine Triphosphate ,0302 clinical medicine ,Polylactic Acid-Polyglycolic Acid Copolymer ,Cell Line, Tumor ,Neoplasms ,medicine ,Animals ,Humans ,General Materials Science ,Amino Acid Sequence ,Human papillomavirus ,Immunity, Cellular ,virus diseases ,Dendritic Cells ,Mice, Inbred C57BL ,Clinical trial ,PLGA ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research ,Nanoparticles ,Female ,Peptides ,Adjuvant - Abstract
Tumor vaccines based on synthetic human papillomavirus (HPV) oncoprotein E7 and/or E6 peptides have shown encouraging results in preclinical model studies and human clinical trials. However, the clinical efficacy may be limited by the disadvantages of vulnerability to enzymatic degradation and low immunogenicity of peptides. To further improve the potency of vaccine, we developed a poly(lactide
- Published
- 2020
- Full Text
- View/download PDF